Could a depression drug help fight opioid addiction?
NCT ID NCT05976646
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether adding a medication called Auvelity (a combination of dextromethorphan and bupropion) to standard buprenorphine treatment is safe and might help reduce cravings, withdrawal, and negative feelings in people with opioid use disorder. 18 adults on stable buprenorphine therapy took part. The main focus was on safety, like heart rate and side effects, while also looking for early signs that the combination could improve treatment outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADDICTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CARI Research Clinic- VCU Institute for Drug and Alcohol Studies
Richmond, Virginia, 23219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tool better measure opioid withdrawal?
- Can a 5-Pill opioid prescription match a 30-Pill one after hip surgery?
- Hidden risk: could opioid misuse be overlooked in cancer care?
- Giving patients a voice in methadone care: a new approach under the microscope
- Can a sleep pill boost success in opioid treatment?
- Can mindfulness curb opioid use after injury?